On a spree, Sanofi scoops up TargeGen in $635M deal

Continuing its global deal-making spree, Sanofi-Aventis has forged a deal to buy San Diego-based TargeGen for $75 million down and up to $560 million in milestones based on the success of its small molecule kinase inhibitors for leukemia, lymphoma and other blood diseases. The deal gives Sanofi control over TargeGen's lead program, TG 101348, a JAK-2 inhibitor which has completed a multicenter clinical Phase I/II trial in patients with myelofibrosis. Myelofibrosis is characterized by a...